Panasonic Receives Highest Award of Brand Design at the Automotive Brand Contest 2020
On June 30, 2020, Panasonic Corporation announced that it has received the highest accolade as Best of Best in the Brand Design category at the Automotive Brand Contest 2020, which is organized by German Design Council (Rat für Formgebung). The award was given in recognition of the concept and design of the Panasonic Automotive business brand. The official award ceremony is planned to take place in autumn 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200629005891/en/
Panasonic Automotive's brand design that received the highest award of brand design at the Automotive Brand Contest 2020 (Graphic: Business Wire)
The Automotive Brand Contest is the only international design competition for automotive brands. The German Design Council, founded in 1953, also runs internationally renowned design awards, such as the German Design Award and the ICONIC Awards.
The Automotive Brand Contest covers all creative aspects in the automotive industry across the world – from vehicle design to corporate publishing. This year's winners also include global brands, such as Audi, BMW, Buick, Byton, Continental, Mercedes-Benz, Porsche and Volkswagen. Panasonic is the first Japanese automotive supplier to be awarded Best of Best in the contest’s history which started in 2011.
In praise of Panasonic Automotive’s brand design, the contest jury said, “The consistent appearance in light blue and green unobtrusively underscores the clear positioning of the Panasonic Automotive brand, where it transitions from a vision into reality, from innovation to automotive solutions, thus becoming convincingly tangible.”
The development of the brand’s concept and design was initiated in Europe from the spring of 2017. The process adopted a collaborative approach with clients. Brand concept and design was developed through basing on clients’ image and expectation on Panasonic. Additionally, several options were reviewed by clients as well as automotive media persons before making the final decision.
Panasonic Automotive’s brand concept and design is adopted not only in Europe but also globally, including China and Japan. It was first presented at its booth at the Shanghai Motor Show in April 2019.
Panasonic continues to strive to enhance the recognition and understandings of its automotive business through the Panasonic Automotive brand and increase the brand value of the company.
About Panasonic
Panasonic Corporation is a global leader developing innovative technologies and solutions for wide-ranging applications in the consumer electronics, housing, automotive, and B2B sectors. The company, which celebrated its 100th anniversary in 2018, operates 528 subsidiaries and 72 associated companies worldwide and reported consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through collaborative innovation, the company uses its technologies to create a better life and a better world for customers. Learn more about Panasonic: https://www.panasonic.com/global.
Source: https://news.panasonic.com/global/topics/2020/79235.html
Related Links
Automotive Company, Panasonic Corporation
https://www.panasonic.com/global/corporate/am.html
Panasonic Business Brands
https://www.panasonic.com/global/corporate/brand/our-brand/business_brand.html
Automotive Brand Contest 2020
https://www.automotive-brand-contest.de/en.html
[Press Release] Toyota and Panasonic Decide to Establish Joint Venture Specializing in Automotive Prismatic Batteries (Feb 3, 2020)
https://news.panasonic.com/global/press/data/2020/02/en200203-4/en200203-4.html
[Press Release] Panasonic Develops a Driverless Automated Valet Parking System and a Large Screen AR-HUD (Oct 11, 2019)
https://news.panasonic.com/global/press/data/2019/10/en191011-2/en191011-2.html
[Press Release] Panasonic to Showcase Booth at 26th ITS World Congress Singapore 2019 (Oct 10, 2019)
https://news.panasonic.com/global/press/data/2019/10/en191010-3/en191010-3.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005891/en/
Contact information
Panasonic Corporation
Global Communications Department
Global PR Office
Click here to go to Media Contact form
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom